Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting

Timothy Muiruri Kinyanjui; Wirichada Pan-Ngum; Sompob Saralamba; Sylvia  Taylor; D James Nokes

doi:10.1016/j.jvacx.2020.100055

Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting

Timothy Muiruri Kinyanjui, Wirichada Pan-Ngum, Sompob Saralamba, Sylvia Taylor, D James Nokes

Applied Mathematics

Research output: Contribution to journal › Article › peer-review

Abstract

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles.

Original language	English
Journal	Vaccine
DOIs	https://doi.org/10.1016/j.jvacx.2020.100055
Publication status	Published - 31 Jan 2020

Access to Document

10.1016/j.jvacx.2020.100055Licence: CC BY

Cite this

@article{c370658e6b9646598091f6f6e5740956,

title = "Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting",

abstract = "Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles. ",

author = "Kinyanjui, {Timothy Muiruri} and Wirichada Pan-Ngum and Sompob Saralamba and Sylvia Taylor and Nokes, {D James}",

year = "2020",

month = jan,

day = "31",

doi = "10.1016/j.jvacx.2020.100055",

language = "English",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting

AU - Kinyanjui, Timothy Muiruri

AU - Pan-Ngum, Wirichada

AU - Saralamba, Sompob

AU - Taylor, Sylvia

AU - Nokes, D James

PY - 2020/1/31

Y1 - 2020/1/31

N2 - Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles.

AB - Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles.

U2 - 10.1016/j.jvacx.2020.100055

DO - 10.1016/j.jvacx.2020.100055

M3 - Article

SN - 0264-410X

JO - Vaccine

JF - Vaccine

ER -

Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting

Abstract

Access to Document

Fingerprint

Cite this